Memantin Pliva (Memantine Hydrochloride)

Memantine hydrochloride is a non‑competitive antagonist of the NMDA receptor ion channel. It blocks prolonged activation by glutamate, limiting calcium influx that can lead to neuronal injury, while allowing normal synaptic transmission needed for learning and memory.

The appropriate dose of Memantin Pliva is set by the prescribing healthcare professional based on the patient’s clinical condition, renal and hepatic function, and tolerability. No fixed regimen is provided here; dosing decisions are individualized.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Memantin Pliva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Pliva belongs to the NMDA receptor antagonist class, whereas drugs such as donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit, while the others are often started earlier in the disease course.

Store Memantin Pliva at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Memantin Pliva is taken orally, usually as a tablet. The medication should be swallowed whole with water, and dosing schedules (once or twice daily) are determined by the prescribing clinician based on individual patient needs.

Serious adverse events can include seizures, cardiac arrhythmias, severe hepatic dysfunction, allergic reactions such as Stevens‑Johnson syndrome, psychosis, and emergence of suicidal thoughts. Patients should be monitored closely for any of these symptoms, especially during dose adjustments.

Memantin Pliva should be avoided in patients with known hypersensitivity to memantine or any excipients, and it is contraindicated in individuals with severe renal impairment unless dose adjustments are made. Caution is also advised for patients with a history of seizures, significant cardiac disease, or active psychiatric disorders.